We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Horizon Discovery Group Plc | LSE:HZD | London | Ordinary Share | GB00BK8FL363 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 184.50 | 184.50 | 185.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMHZD
RNS Number : 6477C
Horizon Discovery Group plc
18 June 2019
Horizon Discovery Group plc
Result of AGM
Cambridge, UK, 18 June 2019: Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Group" or "the Company"), a global leader in the application of gene editing and gene modulation technologies, announces that at its Annual General Meeting held today at 12.00 p.m. at the Company's offices, all resolutions were duly passed.
Ends
For further information from Horizon Discovery Group plc, please contact:
Horizon Discovery Group plc
Terry Pizzie, Chief Executive Officer
Jayesh Pankhania, Chief Financial Officer
Jon Davies, Head of Investor Relations
Tel: +44 (0) 1223 655 580
Numis Securities Limited (Broker and NOMAD)
James Black / Freddie Barnfield / Duncan Monteith
Tel: +44 (0) 207 260 1000
Consilium Strategic Communications (Financial Media and Investor Relations)
Mary-Jane Elliott / Matthew Neal / Melissa Gardiner
Tel: +44 (0) 20 3709 5700
Email: horizon@consilium-comms.com
About Horizon Discovery Group plc www.horizondiscovery.com
Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world leader in gene editing and gene modulation tools and their use. We have more than 10 years' experience of building cell models and our unmatched toolset and expertise enable our customers to answer key questions across research, drug discovery, drug development and diagnostics.
Horizon's platforms and capabilities enable researchers to alter almost any gene or modulate its function in human or mammalian cell-lines. Our customers include many of the world's leading academic institutes and global pharmaceutical companies. Our expertise and insights into the challenges that they face, is driving us to create innovative products and services that not only differentiate our business, but also help our customers to achieve deeper understanding of biological systems, thereby fuelling the development of the next wave of precision medicine.
Horizon is headquartered in Cambridge, UK with offices in USA and Japan. The Group is listed on the London Stock Exchange's AIM market under the ticker HZD.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
RAGCKFDDBBKDNAD
(END) Dow Jones Newswires
June 18, 2019 08:16 ET (12:16 GMT)
1 Year Horizon Discovery Chart |
1 Month Horizon Discovery Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions